SA PRO
Free Account
Legend Biotech CorporationLEGNNASDAQ
LOADING
|||
OverviewNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 94% recommend buying.

Consensus Rating
Buy
18 analysts·Moderate coverage
94%
Rating Distribution
Strong Buy
00%
Buy
1794%
Hold
16%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 187% higher.

Bear Case
$48.00
+117%
Consensus
$63.50
+187%
Bull Case
$75.00
+239%
Price Range18 analysts
Low
Consensus
High
$48.00
$75.00
Current Target
Current Price
$22.14
Upside to Target
$41.36

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.44(9 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+30.58%
EPS+186.97%
FY2028
Rev+27.49%
EPS+57.75%
FY2029
Rev+13.94%
EPS+26.51%

Earnings Surprises

Beat rate:83%(10/12 quarters)
Avg surprise:+31.9%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 7, 2026Oppenheimer
Legend Biotech initiated with an Outperform at Oppenheimer
Target:$75.00
+241.5%from $21.96
Dec 17, 2025Cantor Fitzgerald
Legend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
Target:$74.00
+241.8%from $21.65
Dec 12, 2025Morgan Stanley
Legend Biotech price target lowered to $50 from $83 at Morgan Stanley
Target:$50.00
+120.5%from $22.68
Dec 8, 2025RBC Capital
RBC Capital on Legend Biotech Corp. (LEGN): 'We Would Be Buyers'
Target:$74.00
+201.3%from $24.56
Dec 8, 2025UBS
Legend Biotech price target lowered to $48 from $54 at UBS
Target:$48.00
+70.6%from $28.13
Oct 17, 2025Johnson Rice
Legend Biotech price target lowered to $60 from $75 at H.C. Wainwright
Target:$60.00
+85.4%from $32.36
Jul 2, 2025UBS
Legend Biotech price target lowered to $54 from $60 at UBS
Target:$54.00
+50.4%from $35.91
Mar 12, 2025H.C. Wainwright
Legend Biotech price target raised to $75 from $73 at H.C. Wainwright
Target:$75.00
+101.7%from $37.19
Nov 13, 2024Cantor Fitzgerald
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
Target:$83.00
+48.5%from $55.90
Oct 15, 2024BTIG
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
Target:$91.00
+102.6%from $44.91
Oct 15, 2024Johnson Rice
Legend Biotech weakness a buying opportunity, says Barclays
Target:$94.00
+107.8%from $45.24
Oct 15, 2024Barclays
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
Target:$94.00
+109.3%from $44.91
Oct 8, 2024Redburn Partners
Legend Biotech initiated with a Buy at Redburn Atlantic
Target:$86.00
+73.5%from $49.58
Jun 17, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
Target:$90.00
+114.3%from $42.00
Jun 17, 2024Truist Financial
Legend Biotech initiated with a Buy at Truist
Target:$88.00
+107.3%from $42.45
May 23, 2024Deutsche Bank
Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy
Target:$60.00
+49.9%from $40.04
May 17, 2024Morgan Stanley
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan Stanley
Target:$82.00
+76.8%from $46.37
May 14, 2024RBC Capital
Legend Biotech price target raised to $86 from $85 at RBC Capital
Target:$86.00
+100.1%from $42.97
Apr 17, 2024Scotiabank
Scotiabank Upgrades Legend Biotech Corp. (LEGN) to Sector Outperform
Target:$65.00
+29.7%from $50.12
Apr 3, 2024Cantor Fitzgerald
Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight
Target:$82.00
+45.3%from $56.43
Mar 14, 2024BMO Capital
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
Target:$90.00
+36.1%from $66.11
Dec 6, 2022UBS
UBS Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $66
Target:$66.00
+29.4%from $50.99

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance